GoodRx Holdings Statistics
Total Valuation
GoodRx Holdings has a market cap or net worth of $1.94 billion. The enterprise value is $2.18 billion.
| Market Cap | 1.94B |
| Enterprise Value | 2.18B |
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GoodRx Holdings has 383.61 million shares outstanding. The number of shares has decreased by -3.74% in one year.
| Current Share Class | 106.74M |
| Shares Outstanding | 383.61M |
| Shares Change (YoY) | -3.74% |
| Shares Change (QoQ) | -1.02% |
| Owned by Insiders (%) | 3.21% |
| Owned by Institutions (%) | 21.78% |
| Float | 94.65M |
Valuation Ratios
The trailing PE ratio is 70.12 and the forward PE ratio is 29.81. GoodRx Holdings's PEG ratio is 1.65.
| PE Ratio | 70.12 |
| Forward PE | 29.81 |
| PS Ratio | 2.43 |
| Forward PS | 2.30 |
| PB Ratio | 2.79 |
| P/TBV Ratio | 57.55 |
| P/FCF Ratio | 12.95 |
| P/OCF Ratio | 12.87 |
| PEG Ratio | 1.65 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.47, with an EV/FCF ratio of 14.55.
| EV / Earnings | 76.60 |
| EV / Sales | 2.73 |
| EV / EBITDA | 19.47 |
| EV / EBIT | 23.28 |
| EV / FCF | 14.55 |
Financial Position
The company has a current ratio of 5.23, with a Debt / Equity ratio of 0.83.
| Current Ratio | 5.23 |
| Quick Ratio | 4.94 |
| Debt / Equity | 0.83 |
| Debt / EBITDA | 4.51 |
| Debt / FCF | 3.61 |
| Interest Coverage | 1.91 |
Financial Efficiency
Return on equity (ROE) is 4.43% and return on invested capital (ROIC) is 4.61%.
| Return on Equity (ROE) | 4.43% |
| Return on Assets (ROA) | 4.26% |
| Return on Invested Capital (ROIC) | 4.61% |
| Return on Capital Employed (ROCE) | 7.85% |
| Revenue Per Employee | $1.08M |
| Profits Per Employee | $38,551 |
| Employee Count | 738 |
| Asset Turnover | 0.58 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GoodRx Holdings has paid $19.38 million in taxes.
| Income Tax | 19.38M |
| Effective Tax Rate | 40.52% |
Stock Price Statistics
The stock price has decreased by -35.36% in the last 52 weeks. The beta is 1.24, so GoodRx Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 1.24 |
| 52-Week Price Change | -35.36% |
| 50-Day Moving Average | 4.36 |
| 200-Day Moving Average | 4.99 |
| Relative Strength Index (RSI) | 68.14 |
| Average Volume (20 Days) | 1,700,905 |
Short Selling Information
The latest short interest is 4.56 million, so 1.19% of the outstanding shares have been sold short.
| Short Interest | 4.56M |
| Short Previous Month | 4.29M |
| Short % of Shares Out | 1.19% |
| Short % of Float | 4.82% |
| Short Ratio (days to cover) | 3.72 |
Income Statement
In the last 12 months, GoodRx Holdings had revenue of $797.41 million and earned $28.45 million in profits. Earnings per share was $0.07.
| Revenue | 797.41M |
| Gross Profit | 748.30M |
| Operating Income | 93.61M |
| Pretax Income | -59.30M |
| Net Income | 28.45M |
| EBITDA | 111.92M |
| EBIT | 93.61M |
| Earnings Per Share (EPS) | $0.07 |
Balance Sheet
The company has $300.98 million in cash and $541.19 million in debt, giving a net cash position of -$240.21 million or -$0.63 per share.
| Cash & Cash Equivalents | 300.98M |
| Total Debt | 541.19M |
| Net Cash | -240.21M |
| Net Cash Per Share | -$0.63 |
| Equity (Book Value) | 654.35M |
| Book Value Per Share | 1.81 |
| Working Capital | 436.83M |
Cash Flow
In the last 12 months, operating cash flow was $150.72 million and capital expenditures -$975,000, giving a free cash flow of $149.74 million.
| Operating Cash Flow | 150.72M |
| Capital Expenditures | -975,000 |
| Free Cash Flow | 149.74M |
| FCF Per Share | $0.39 |
Margins
Gross margin is 93.84%, with operating and profit margins of 11.74% and 3.57%.
| Gross Margin | 93.84% |
| Operating Margin | 11.74% |
| Pretax Margin | 6.00% |
| Profit Margin | 3.57% |
| EBITDA Margin | 14.04% |
| EBIT Margin | 11.74% |
| FCF Margin | 18.78% |
Dividends & Yields
GoodRx Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.74% |
| Shareholder Yield | 3.74% |
| Earnings Yield | 1.47% |
| FCF Yield | 7.72% |
Analyst Forecast
The average price target for GoodRx Holdings is $6.33, which is 25.22% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.33 |
| Price Target Difference | 25.22% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 6.37% |
| EPS Growth Forecast (5Y) | 83.68% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GoodRx Holdings has an Altman Z-Score of 1.98 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.98 |
| Piotroski F-Score | 7 |